Nureca share price
NSE: NURECAPharma & HealthcareMedical Devices
Nureca at a glance
Nureca (NSE: NURECA) closed at ₹338.50 on 22 Oct 2026, up 2.92% on the day. With a market capitalisation of ₹323 Cr, it ranks 2009th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Devices.
At its last close the stock traded at 159.7× trailing earnings, against a return on equity of 1.2% in FY26. Over the past year the share price has risen 44.4%. Its 52-week range is ₹204.00 (30 Mar 2026) to ₹376.00 (30 Sep 2026); the last close is 10.0% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹40 Cr (+18.0% year on year) and net profit ₹3 Cr (+279.0%), on a consolidated basis. Promoters held 68.09% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹323 CrRank 2009 on NSE
- P/E (trailing)
- 159.7×
- Price to book
- 1.09×FY26
- EPS (TTM)
- ₹4.30to Q1 FY27
- ROE
- 1.2%FY26
- ROCE
- 3.4%FY26
- Debt to equity
- 0FY26
- Net profit margin
- 1.4%FY26
- Book value / share
- ₹189.44FY26
- 52-week high
- ₹376.0030 Sep 2026
- 52-week low
- ₹204.0030 Mar 2026
- 1-year return
- +44.4%
- RSI (14-day)
- 53
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +2.92% | +4.5% | −0.3% | +10.6% | +44.4% |
Nureca quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹31 Cr | ₹26 Cr | ₹32 Cr | ₹34 Cr | ₹38 Cr | ₹40 Cr | ₹35 Cr | ₹40 Cr |
| Revenue YoY | −0.5% | +18.3% | +87.0% | +68.6% | +21.0% | +49.8% | +11.6% | +18.0% |
| Net profit | −₹0 Cr | −₹3 Cr | ₹2 Cr | ₹1 Cr | ₹4 Cr | ₹4 Cr | −₹6 Cr | ₹3 Cr |
| Net profit YoY | −116.6% | −1,747.1% | — | −51.2% | — | — | −346.6% | +279.0% |
| Net margin | −1.5% | −10.6% | 7.8% | 2.4% | 9.6% | 9.4% | −17.2% | 7.6% |
| EPS | −₹0.48 | −₹2.80 | ₹2.47 | ₹0.81 | ₹3.63 | ₹3.91 | −₹6.45 | ₹3.21 |
Nureca financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹213 Cr | ₹256 Cr | ₹111 Cr | ₹92 Cr | ₹110 Cr | — |
| Operating profit | ₹62 Cr | ₹61 Cr | −₹11 Cr | −₹3 Cr | ₹1 Cr | — |
| Net profit | ₹46 Cr | ₹45 Cr | −₹8 Cr | −₹2 Cr | ₹1 Cr | — |
| EPS (₹) | ₹62.00 | ₹45.00 | −₹8.00 | −₹2.00 | ₹1.00 | — |
| Cash from operations | ₹35 Cr | ₹1 Cr | ₹10 Cr | −₹3 Cr | −₹19 Cr | — |
| Total debt | ₹3 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr |
| Shareholders' equity | ₹163 Cr | ₹203 Cr | ₹195 Cr | ₹193 Cr | ₹194 Cr | ₹181 Cr |
Nureca shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 7 Jan 2026 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 64.33% | 64.97% | 64.97% | 68.09% | 68.09% | 68.09% |
| Foreign institutions | 0.07% | 0.07% | 0.08% | 0.08% | 0.28% | 0.11% |
| Domestic institutions | 0.04% | 0.04% | 0.04% | 0.04% | 0.24% | 0.24% |
| Non-institutions | 35.56% | 34.92% | 34.91% | 31.79% | 31.39% | 31.57% |
Nureca vs peers
The listed Pharma & Healthcare companies nearest to Nureca by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| MEDICAMEQMedicamen Biotech | ₹266.50 | −0.11% | −14.0% | ₹361 Cr | 36.9 | — |
| ASTALLTDAstal Lab | — | — | — | ₹358 Cr | — | — |
| NURECANureca | ₹338.50 | +2.92% | +44.4% | ₹323 Cr | 159.7 | — |
| AAREYDRUGSAarey Drugs & Pharmaceuticals | ₹111.75 | −0.84% | +31.2% | ₹317 Cr | 80.4 | — |
| LYKALABSLyka Labs | ₹82.64 | −1.99% | −13.2% | ₹299 Cr | — | — |
| BIJHANSBijoy Hans | — | — | — | ₹292 Cr | — | — |
| ASTONEALABAstonea Labs | — | — | — | ₹281 Cr | — | — |
Ask anything about Nureca
Pivot answers on the live chart with evidence you can check, and tests strategies against NURECA's own history. Try: “Why has NURECA moved over the last three months?” · “Backtest a 50-day moving-average crossover on NURECA over five years” · “Compare NURECA with MEDICAMEQ on margins and valuation”
Frequently asked questions about Nureca
What is the share price of Nureca today?
Nureca (NSE: NURECA) last closed at ₹338.50 on 22 Oct 2026. Its 52-week high is ₹376.00 and its 52-week low is ₹204.00.
What is the market cap of Nureca?
Nureca's market capitalisation is ₹323 Cr (₹323 Cr) at the 22 Oct 2026 close, ranking 2009th among the NSE companies Pivot tracks.
What is the P/E ratio of Nureca?
Nureca trades at a trailing P/E of 159.7.
What is the ROE and ROCE of Nureca?
Return on equity was 1.2% in FY26 and return on capital employed was 3.4% in FY26 (consolidated figures).
Is Nureca a debt-free company?
Nureca is close to debt-free: its debt-to-equity ratio was 0 in FY26.
What were Nureca's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Nureca reported revenue of ₹40 Cr, +18.0% year on year, and net profit of ₹3 Cr, +279.0% year on year.
How has Nureca stock performed over the last year?
Nureca's share price has risen 44.4% over the past year, +10.6% over three months and −0.3% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Nureca?
As of 30 Jun 2026: promoters 68.09%, foreign institutions 0.11%, domestic institutions 0.24%, non-institutions 31.57%.
Who are Nureca's competitors?
The listed Pharma & Healthcare companies closest to Nureca by market cap are Medicamen Biotech, Astal Lab, Aarey Drugs & Pharmaceuticals, Lyka Labs, Bijoy Hans and Astonea Labs.
Is Nureca a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Nureca's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on NURECA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with N · all NSE stocks · this page as text